Features of management of patients with acute tonsillopharyngitis

Introduction. The prevalence of acute and chronic rhinitis determines the socio-economic side of the issue and requires effective treatment and improvement of patients’ quality of life. Aim. To study the effectiveness of the drug Strepsils® Intensive in patients with acute tonsillopharyngitis in different age groups. Mat erials and methods. 143 patients were examined, of whom 36 adolescents (mean age 14.7 ± 3.4 years) and 34 adults (mean age 29.9 ± 7.1 years) were selected. All patients included in the study received Strepsils® Intensive for resorption, one tablet every 3–6 hours (5 tablets per day) for 3 days. To assess the dynamics of complaints, a 10-point visual analogue scale (VAS) was used; additional assessment included mesopharyngoscopy data on the 1st, 2nd and 3rd days of observation. Patient satisfaction with treatment and the occurrence of adverse reactions were studied. Results and discussion. Evaluation of treatment results using a 10-point VAS showed a significantly significant (p < 0.05) improvement in the well-being of patients in both groups when prescribed the drug Strepsils® Intensive. By the 1st day of treatment with Strepsils® Intensive, sore throat in adult patients decreased by 46% (4.1 ± 0.3 points) (p < 0.05). The dynamics of the severity of sore throat in the group of adolescents decreased by 60.2% (5.3 ± 0.1 points). There was a decrease in difficulty swallowing by 50% in adults and by 60.5% in adolescents. By the end of the observation, the pharyngoscopy picture was normalized in both groups in 97% of cases. Patient satisfaction with the effectiveness of treatment was rated as excellent in 95.7% (n = 67), and as average in 4.3% (n = 3). Conclusions. The use of the drug Strepsils® Intensive is advisable in the treatment of acute tonsillopharyngitis in adolescents and adults against the background of ARVI as an effective means of relieving the severity of symptoms.